Jeremy Chataway

9.6k total citations · 1 hit paper
171 papers, 5.1k citations indexed

About

Jeremy Chataway is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Jeremy Chataway has authored 171 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Pathology and Forensic Medicine, 45 papers in Neurology and 33 papers in Rheumatology. Recurrent topics in Jeremy Chataway's work include Multiple Sclerosis Research Studies (119 papers), Rheumatoid Arthritis Research and Therapies (22 papers) and Peripheral Neuropathies and Disorders (21 papers). Jeremy Chataway is often cited by papers focused on Multiple Sclerosis Research Studies (119 papers), Rheumatoid Arthritis Research and Therapies (22 papers) and Peripheral Neuropathies and Disorders (21 papers). Jeremy Chataway collaborates with scholars based in United Kingdom, Italy and United States. Jeremy Chataway's co-authors include Anisha Doshi, Robert J. Fox, David Clayton, Robert Feakes, Hywel B. Jones, Peter N. Goodfellow, Julia Gray, Daniel Ontaneda, Alastair Compston and Stephen Sawcer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Jeremy Chataway

157 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

2014 304 citations Jeremy Chataway, Jennifer M. Nicholas et al. profile →

Peers

Countries citing papers authored by Jeremy Chataway

Since Specialization

Citations

This map shows the geographic impact of Jeremy Chataway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Chataway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Chataway more than expected).

Fields of papers citing papers by Jeremy Chataway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Chataway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Chataway. The network helps show where Jeremy Chataway may publish in the future.

Co-authorship network of co-authors of Jeremy Chataway

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Chataway. A scholar is included among the top collaborators of Jeremy Chataway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Chataway. Jeremy Chataway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Approach to JCV testing with natalizumab biosimilar: a UK consensus statement 2025 ·Multiple Sclerosis and Related Disorders ·Ruth Dobson, Tarunya Arun, James Varley, Jeremy Chataway, Wallace Brownlee, Paul W. Gallagher, (unknown), Orla Gray, Gillian Ingram, Niall MacDougall, Paolo A. Muraro, Katy Murray, David Paling, (unknown), (unknown), Emma Tallantyre, S. Anand Trip, Alasdair Coles	0
2	CSF1R -Related Disorder 2024 ·Neurology Genetics ·(unknown), (unknown), Jeremy Chataway, Henry Houlden, David S. Lynch	5
3	Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England 2024 ·Multiple Sclerosis Journal ·Raffaele Palladino, Jeremy Chataway, (unknown), Azeem Majeed, Ruth Ann Marrie	0
4	Analysis of GFAP variants in UK Biobank suggests underdiagnosis or incomplete penetrance of adult-onset Alexander disease 2024 ·Journal of Neurology Neurosurgery & Psychiatry ·Delia Gagliardi, (unknown), (unknown), Henry Houlden, Jeremy Chataway, Frederik Barkhof, David S. Lynch	0
5	The Impact of Relapses on Pain and Quality of Life in Patients with Multiple Sclerosis Treated with Corticosteroids 2023 ·Pharmaceuticals ·Martin Rakuša, Jeremy Chataway, Todd A. Hardy	1
6	Enhancing involvement of people with multiple sclerosis in clinical trial design 2023 ·Multiple Sclerosis Journal ·Emma Gray, (unknown), (unknown), (unknown), Susan C. Scott, Guy Peryer, Marie Braisher, Cheryl Pugh, (unknown), Ruth Ann Marrie, Maria Pia Sormani, Jeremy Chataway	8
7	Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices 2023 ·Patient ·Edward Webb, David Meads, (unknown), Helen Ford, Hilary Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue Pavitt, Klaus Schmierer, Ana Manzano	2
8	Decentralised clinical trials in multiple sclerosis research 2022 ·Multiple Sclerosis Journal ·Afagh Garjani, (unknown), Christopher Allen, Douglas Gunzler, (unknown), Sarah M. Planchon, Roshan das Nair, Jeremy Chataway, Emma Tallantyre, Daniel Ontaneda, Nikos Evangelou	4
9	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis 2022 ·Neurology ·Vivien Li, Baptiste Leurent, Frederik Barkhof, Marie Braisher, Fay Cafferty, Olga Ciccarelli, Arman Eshaghi, Emma Gray, Jennifer M. Nicholas, Mahesh Parmar, Guy Peryer, (unknown), Nigel Stallard, James Wason, Jeremy Chataway	12
10	The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis 2022 ·Multiple Sclerosis Journal ·Nancy D. Chiaravalloti, John DeLuca, Amber Salter, Maria Pia Amato, Giampaolo Brichetto, Jeremy Chataway, Ulrik Dalgas, Rachel Farrell, Peter Feys, Massimo Filippi, Jennifer Freeman, Matilde Inglese, (unknown), Nancy B. Moore, Robert W. Motl, Maria A. Rocca, Brian M. Sandroff, Gary Cutter, Anthony Feinstein	8
11	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease 2022 ·BMJ Open ·(unknown), Rachel Dakin, J Williamson, Judith Newton, (unknown), Shuna Colville, Maria Stavrou, Jenna M. Gregory, (unknown), Arpan R. Mehta, Jeremy Chataway, Robert Swingler, Richard Parker, Christopher J. Weir, Nigel Stallard, Mahesh Parmar, Malcolm Macleod, Suvankar Pal, Siddharthan Chandran	18
12	The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments 2020 ·Patient ·Edward Webb, David Meads, (unknown), Helen Ford, Hilary Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue Pavitt, Klaus Schmierer, Ana Manzano	7
13	Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis 2020 ·Patient Education and Counseling ·Ana Manzano, (unknown), Helen Ford, Hilary Bekker, Barbara Potrata, Jeremy Chataway, Klaus Schmierer, George Pepper, David Meads, Edward Webb, Sue Pavitt	11
14	Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis 2020 ·Multiple Sclerosis and Related Disorders ·Ana Manzano, (unknown), Helen Ford, Sue Pavitt, Barbara Potrata, Klaus Schmierer, Jeremy Chataway, Edward Webb, David Meads, George Pepper, Hilary Bekker	13
15	82 Evaluating the risk of macrovascular events and mortality in individuals with multiple sclerosis in England: a population-based nested case-control study 2019 ·UCL Discovery (University College London) ·Raffaele Palladino, Ruth Ann Marrie, Amna Majeed, Jeremy Chataway	1
16	Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin 2019 ·Multiple Sclerosis and Related Disorders ·Roberta Lanzillo, Marcello Moccia, Cinzia Valeria Russo, Antonio Carotenuto, Agostino Nozzolillo, Martina Petruzzo, Raffaele Palladino, Jeremy Chataway, Vincenzo Brescia Morra	8
17	Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis 2018 ·Multiple Sclerosis and Related Disorders ·(unknown), Ana Manzano, George Pepper, Sue Pavitt, Helen Ford, Hilary Bekker, Jeremy Chataway, Klaus Schmierer, David Meads, Edward Webb, Barbara Potrata	24
18	Negotiating the radiologically isolated syndrome 2014 ·British Journal of Hospital Medicine ·Alice Kate G. Cummings, Jeremy Chataway	2
19	Multiple sclerosis. 2007 ·PubMed ·Richard Nicholas, Jeremy Chataway	2
20	Developing a measure of patients' experiences of relapse management in multiple sclerosis. 2003 ·UCL Discovery (University College London) ·Afsane Riazi, JC Hobart, Bernadette Porter, Jeremy Chataway, Alan J. Thompson	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact